[Therapeutic target for endothelium-derived hyperpolarizing factor signaling in diabetic vascular complication].
Vascular tone is tightly regulated by endothelium-derived factors. These include relaxing factors (EDRFs) such as nitric oxide (NO), hyperpolarizing factors (EDHFs), and contracting factors (EDCFs). Although EDHF is a prominent vasodilator, particularly in smaller arteries, little attention has been paid to the potential role of EDHF responses in diabetes. EDHF signaling may involve various factors, including several diffusible factors and non-diffusible factors (e.g., gap junctions). It has been demonstrated that the alterations in EDHF relaxation seen in mesenteric arteries from diabetic rats may be attributable to an increase in phosphodiesterase 3 (PDE3) activity, leading to a reduction in the action of adenosine 3',5'-cyclic monophosphate (cAMP), and consequently the activity of protein kinase A (PKA) is decreased in such arteries. Moreover, it has been suggested that the imbalance between EDRFs and EDCFs is present in mesenteric arteries from type 2 diabetic rats and the EDHF relaxation can be partly reversed by suppression of EDCF signaling. Indeed, chronic treatment with metformin, eicosapentaenoic acid, or thromboxane synthase inhibitor can reduce EDCF signaling and normalize EDHF signaling in mesenteric arteries from type 2 diabetic rats. Although the improvement or restoration of EDHF responses has not been the direct subject of any pharmaceutical effort, increasing cAMP/PKA signaling (e.g., by inhibiting PDE3 activity) or reducing EDCFs signaling has potential as an interesting therapeutic target in diabetic vasculopathy.
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University. t-matsu@hoshi.ac.jp
Takayuki
T
Matsumoto
D000818:Animals; D001685:Biological Factors / Q000502:physiology*; D000242:Cyclic AMP / Q000502:physiology; D003924:Diabetes Mellitus, Type 2; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000235:genetics*; D004195:Disease Models, Animal; D015195:Drug Design; D016232:Endothelins / Q000502:physiology; D045462:Endothelium-Dependent Relaxing Factors / Q000502:physiology; D051381:Rats; D020334:Rats, Inbred OLETF; D015398:Signal Transduction / Q000502:physiology*
D001685:Biological Factors; D016232:Endothelins; D045462:Endothelium-Dependent Relaxing Factors; C067410:endothelium-dependent hyperpolarization factor; D000242:Cyclic AMP